ITI with high-dose FIX and combined immunosuppressive therapy in a patient with severe haemophilia B and inhibitor

Hamostaseologie

Volumn 29, Issue 2, 2009, Pages 155-157

  Beutel, K ^a   Hauch, H ^b   Rischewski, J ^c   Kordes, U ^a   Schneppenheim, J ^d   Schneppenheim, R ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d UNIVERSITY OF KIEL   (Germany)

Author keywords

Haemophilia B; Immune tolerance induction; Immunosuppression; Inhibitor

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BERININ; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9 CONCENTRATE; BLOOD CLOTTING FACTOR 9 INHIBITOR; BLOOD CLOTTING INHIBITOR; DEXAMETHASONE; IMMUNOGLOBULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RITUXIMAB; STEROID; UNCLASSIFIED DRUG;

ALLERGIC REACTION; ARTICLE; BLEEDING; CASE REPORT; DRUG MEGADOSE; HEMARTHROSIS; HEMOPHILIA B; HUMAN; HYPOVOLEMIC SHOCK; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGICAL TOLERANCE INDUCTION THERAPY; IMMUNOSUPPRESSIVE TREATMENT; INFANT; MALE; MUSCLE BLEEDING; NEPHROTIC SYNDROME; PROTEINURIA; URINALYSIS; URTICARIA;

EID: 66749168406     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1617018     Document Type: Article

References (19)

1. Alexander S, Hopewell S, Hunter S, Chouksey A. Rituximab and desensitization for a patient with severe factor IX deficiency, inhibitors, and history of anaphylaxis. J Pediatr Hematol Oncol 2008; 30: 93-95.
2. Astermark J, Morado M, Rocino A et al. Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors. Haemophilia 2006; 12: 363-371.
3. Barnes C, Rudzki Z, Ekert H. Induction of immune tolerance and suppression of anaphylaxis in a child with haemophilia B by simple plasmapheresis and antigen exposure. Haemophilia 2000; 6: 693-695.
4. Chuansumrit A, Moonsup Y, Sirachainan N et al. The use of rituximab as an adjuvant for immune tolerance therapy in a hemophilia B boy with inhibitor and anaphylaxis to factor IX concentrate. Blood Co- agul Fibrinolysis 2008; 19: 208-211.
5. Cross DC, van der Berg HM. Cyclosporin A can achieve immune tolerance in a patient with severe haemophilia B and refractory inhibitors. Haemophilia 2007; 13: 111-114.
6. Dimichele D. The North American Immune Tolerance Registry: contributions to the thirty-year experience with immune tolerance therapy. Haemophilia. 2009; 15: 320-328.
7. DiMichele DM, Kroner BL. The North American Immune Tolerance Registry: practices, outcomes, outcome predictors. Thrombosis and haemostasis. 2002; 87: 52-57.
8. Ehrenforth S, Kreuz W, Scharrer I et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 594-598.
9. Fox RA, Neufeld EJ, Bennett CM. Rituximab for adolescents with haemophilia and high titre inhibitors. Haemophilia 2006; 12: 218-222.
10. Freiburghaus C, Berntorp E, Ekman M et al. Tolerance induction using the Malmo treatment model 1982-1995. Haemophilia 1999; 5: 32-39.
11. Hay CR, Brown S, Collins PW et al. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation. Br J Haematol 2006; 133: 591-605.
12. Klarmann D, Martinez Saguer I, Funk MB et al. Immune tolerance induction with mycophenolate- mofetil in two children with haemophilia B and inhibitor. Haemophilia 2008; 14: 44-49.
13. Mathias M, Khair K, Hann I, Liesner R. Rituximab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe haemophilia. Br J Haematol 2004; 125: 366-368.
14. Shibata M, Shima M, Misu H et al. Management of haemophilia B inhibitor patients with anaphylactic reactions to FIX concentrates. Haemophilia 2003; 9: 269-271.
15. Stasi R, Brunetti M, Stipa E, Amadori S. Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia. Blood 2004; 103:4424-4428.
16. Suzuki N, Watanabe J, Kudoh T et al. Successful induction of immune tolerance in a patient with haemophilia B with inhibitor. Haemophilia 2003; 9: 340-342.
17. Warrier I. Management of haemophilia B patients with inhibitors and anaphylaxis. Haemophilia 1998; 4: 574-576.
18. Warrier I, Ewenstein BM, Koerper MA et al. Factor IX inhibitors and anaphylaxis in hemophilia Br J Pediatr Hematol Oncol 1997; 19: 23-27.
19. Wermes C, von Depka Prodzinski M, Welte K KW S. New strategy for the treatment of factor IX inhibitors in severe haemophilia B. Blood 2000; 96: 647a.